No Data
No Data
Brackets, Best One Dotcom, etc.
<4166> KAKKO CO., LTD. SBI Investment Co., Ltd. shareholding ratio 5.01% → 4.78%, reporting obligation arise on June 12, 2024. <4199> Wonderplanet Inc. Atsushi Ishikawa shareholding ratio 10.47% → 8.91%, reporting obligation arise on May 1, 2024. <4199> Wonderplanet, Inc. Yuki Tokikawa shareholding ratio 17.14% → 15.38%, reporting obligation arise on 20.
Kids' Bio, Cringle, and others.
<2997> Implementation of the Storage King shareholder benefits and introduction of shareholder benefit system <4563> Ange's 44th new share subscription right (with exercise price adjustment clause) Large-scale exercise of subscription rights, 3.9 million shares delivered from the 18th <4584> Kids Bio Caiohm Biosciences <4583> Signed a business alliance agreement for the joint development of new biosimilars <4882> Perseus large-scale exercise of the 28th new share subscription right (with exercise price adjustment clause), 370,200 shares delivered from the 14th.
Classy Com, Ailick, and others.
<151A> Dai Business School's operation and training contract business acquired all shares of 宿屋塾 and became a subsidiary. <3497> LeTech revised its financial estimates and is expected to achieve revenue of 14.5 billion yen this fiscal year <- 21.4 billion yen. <4014> Karada Note upwardly revised its operating profit forecasts for this fiscal year from 50 million yen to 100 million yen. <4168> Fuller, which handles yapply digital partner business, signed a capital business alliance agreement and acquired some of Fuller's shares. <4378> CINC has upwardly revised its financial estimates this fiscal year.
Anges - Supply contract for "Zokinvy"
On the 6th, Anges (4563) announced that Sentynl has taken over Eiger's contractual position for the supply agreement of 'Zokinvy' that the company had signed with Eiger. The company announced that on May 8, 2024, the business transfer destination of Eiger BioPharmaceuticals' (Eiger) 'Zokinvy' business has been determined to be Sentynl Therapeutics (Sentynl), a US bio-pharmaceutical company.
Anges --- Co-developed Tie2 receptor agonist (AV-001) has obtained fast track designation from the US FDA
Anges <4563> announced on the 29th that the treatment drug “Tie2 receptor agonist (AV-001)” for acute respiratory distress syndrome (ARDS), which is being jointly developed with Vasomune in the United States, has obtained fast track designation from the US Food and Drug Administration (FDA). ARDS is a condition that causes severe respiratory failure, and there are currently no effective treatments. The FDA's fast track designation indicates that “AV-001” is expected as a therapeutic agent, and this indicates
Material groups, learning aids, etc.
<156A>Material Group Co., Ltd. 10X Investment LTD (10X Investment LTD.) Stock Ownership Ratio 11.46% → 10.20% Reporting Obligation Date 2024/04/25 <156A>Material Group Co., Ltd. AP60 Stock Ownership Ratio 35.55% → 31.63% Reporting Obligation Date 2024/04/25 <184A>Learning Aid K & Co., Ltd.
No Data